- Home
- CAN vs PACB Comparison
CAN vs PACB Comparison
Compare CAN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | PACB |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | 575 |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.0M | 459.0M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CAN | PACB |
|---|---|---|
| Price | $0.50 | $1.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $3.09 | $2.20 |
| AVG Volume (30 Days) | ★ 12.1M | 5.9M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | $63.64 | $12.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $0.43 | $0.85 |
| 52 Week High | $2.22 | $2.73 |
Technical Indicators
Market Signals| Indicator | CAN | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 33.19 |
| Support Level | $0.43 | $1.36 |
| Resistance Level | $0.80 | $1.73 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 47.27 | 5.66 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.